Assessing the risk of bone fracture among postmenopausal women who are receiving adjuvant hormonal therapy for breast cancer

Current Medical Research and Opinion

Volumn 23, Issue 5, 2007, Pages 1045-1051

  Bell, Richard ^a,c   Lewis, J ^b  

^a GEELONG HOSPITAL   (Australia)

^b ASTRAZENECA   (United Kingdom)

^c Andrew Love Cancer Centre   (Australia)

Author keywords

Anastrozole; Aromatase inhibitors; Bone fracture; Breast cancer; Postmenopausal; Tamoxifen

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVOR; CONTROLLED STUDY; DRUG SAFETY; EARLY CANCER; FEMALE; FOLLOW UP; FRACTURE; HIGH RISK POPULATION; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE; RISK ASSESSMENT; RISK FACTOR;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; COLLES' FRACTURE; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; NITRILES; POSTMENOPAUSE; RISK ASSESSMENT; TAMOXIFEN; TRIAZOLES; WRIST INJURIES;

EID: 34249081449     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079907X187919     Document Type: Article

References (30)

1. Buzdar A, Chlebowski R, Cuzick J, et al. Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer. Curr Med Res Opin 2006;22:1575-85
2. Buzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7:633-43
3. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-2
4. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial efficacy and safety update analysis. Cancer 2003;98:1802-10
5. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002;359:2131-9
6. Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:2747-57
7. Coombes RC, Hall E, Gibson LJ, et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;50:1081-92
8. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455-62
9. Goss PE, Ingle JN, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-802
10. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Nad Cancer Inst 2005;97:1262-71
11. Heshmati HM, Khosla S, Robins SP, et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002;17:172-8
12. Ismail AA, Pye SR, Cockerill WC, et al. Incidence of limb fracture across Europe: Results from the European Prospective Osteoporosis Study. Osteoporos Int 2002;13:565-71
13. Howell A. Effect of anastrozole on bone mineral density: 2-year results of the 'Arimidex' (anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial. Breast Cancer Res Treat 2003;82: S27 (Abstract 129)
14. Loønning PE, Geisler J, Krag LE, et al. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol 2005;23:5126-37
15. Perez EA, Josse RG, Pritchard KI, et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol. 2006;24:3629-35
16. Coleman R, et al. Effect of anastrozole on bone mineral density: 5-year results form 'Arimidex, Tamoxifen, Alone or in Combination (ATAC) trial'. J Clin Oncol 2006;24:18S (Abstract 511)
17. Love RR, Barden HS, Mazess R, et al. Effect of tamoxifen on lumbar spine bone mineral density in postmenopausal women after 5 years. Arch Intern Med 1994;154:2585-8
18. Neele SJ, Evertz R, De Valk-De Roo G, et al. Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 2002;30:599-603
19. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-I Study. J Natl Can Inst 1998;90:1371-88
20. Bell R, Sambrook P, Chen Z, Lewis J. Relative risk for fractures in postmenopausal women, postmenopausal breast cancer survivors and postmenopausal women managed with adjuvant hormonal therapy. Eur J Cancer 2006;4:95 (Abstract 175)
21. Chen Z, Maricic M, Bassford TL, et al. Fracture risk among breast cancer survivors: Results from the Women's Health Initiative Observational Study. Arch Intern Med 2005;165: 552-8
22. Cooley H, Jones G. A population-based study of fracture incidence in southern Tasmania: Lifetime fracture risk and evidence for geographic variations within the same country. Osteoporosis Int 2001;12:124-30
23. Greep NC, Giuliano AE, Hansen NM, et al. The effects of adjuvant chemotherapy on bone density in postmenopausal women with early breast cancer. Am J Med 2003;114: 653-9
24. Firipis M. Managing osteoporosis in women with breast cancer. In: Clinical Updates in Breast Cancer 2006;1:8-10
25. Brufsky A, Harker WG, Beck JT, et al. Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 2007;25:829-36
26. Davidson N, Neven P, Llombart A, et al. Zoledronic acid in the prevention of cancer treatment-induced bone loss in post-menopausal women receiving letrozole as adjuvant therapy for early breast cancer. Breast 2005;14(Suppl 1):S44 (Abstract P105)
27. Brufsky A. Management of cancer-treatment-induced bone loss in postmenopausal women undergoing adjuvant breast cancer therapy: A Z-FAST update. Semin Oncol 2006;33:13-17
28. Osteoporosis Australia. Medical Only, an insert in Osteoblast, Summer 2004
29. Hillner BE, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:4042-57
30. Australian Clinical Trials Registry. Available at: www.actr.org. au [Last accessed 13 February 2007